Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Current Deferred Revenue (2025)

Coeptis Therapeutics Holdings has reported Current Deferred Revenue over the past 1 years, most recently at $599455.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $599455.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $599455.0 (changed N/A YoY), and the annual figure for FY2025 was $599455.0, changed.
  • Current Deferred Revenue for Q4 2025 was $599455.0 at Coeptis Therapeutics Holdings, down from $1.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for COEPW hit a ceiling of $1.6 million in Q2 2025 and a floor of $599455.0 in Q4 2025.